Recurrent EGFR Alterations in NTRK3 Fusion Negative Congenital Mesoblastic Nephroma

Overview

Journal Pract Lab Med

Specialty Biochemistry

Date 2020 Jun 4

PMID 32490123

Citations 4

Authors

Li Lei

Bradley A Stohr

Stacey Berry

Christina M Lockwood

Jessica L Davis

Erin R Rudzinski

Christian A Kunder

Affiliations

Soon will be listed here.

Abstract

Objectives: To identify oncogenic driver mutations in congenital mesoblastic nephroma (CMN) cases lacking - fusion and discuss their diagnostic value.

Design: The institutional pathology database was queried for cases with a morphologic diagnosis of CMN. Cases positive for rearrangement or with unavailable blocks were excluded. Four cases met the inclusion criteria and were sequenced by next-generation sequencing. Three additional cases were contributed by our collaborators.

Results: Three of four internal cases harbor an kinase domain duplication (KDD), which is known to be oncogenic yet exceedingly rare in other histologies. All three outside cases are positive for alterations, including KDD in two and a splicing site mutation in one. The splicing site mutation is predicted to be EGFR activating. One of the outside cases was a retroperitoneal mass without a clear site of origin. A diagnosis of CMN is suggested based on exclusion of differential diagnoses by expert consultation and detection of KDD.

Conclusions: EGFR activation, predominantly via KDD, is a common recurrent genetic alteration in CMN lacking fusions. CMN can be molecularly classified into fusion type, EGFR activation type and others.

Citing Articles

Adjunctive diagnostic tool for histopathological classification of congenital mesoblastic nephroma based in molecular genetic findings.

Hamada H, Kohashi K, Iwasaki T, Hashisako M, Hino Y, Fukuhara M J Cancer Res Clin Oncol. 2025; 151(2):69.

PMID: 39921750 PMC: 11807071. DOI: 10.1007/s00432-025-06116-x.

Coexisting Congenital Mesoblastic Nephroma and Lissencephaly: Unique Case Report with Pathological Analysis and Its Clinical Significance.

Zakic H, Kontic Vucinic O, Stamenkovic J, Jevtic J, Perisic Mitrovic M, Zivotic M Biomedicines. 2025; 13(1.

PMID: 39857780 PMC: 11762540. DOI: 10.3390/biomedicines13010196.

Poor outcome in congenital mesoblastic nephroma with fusion: a case report from multi-disciplinary treatment to molecular tumor board.

Sun M, Chen J, Xue Y, Deng Y, Mater D, Hiemcke-Jiwa L Transl Pediatr. 2024; 13(6):976-986.

PMID: 38984028 PMC: 11228910. DOI: 10.21037/tp-24-126.

Case report of an infant with congenital mesoblastic nephroma leading to pulmonary metastasis.

Athapathu A, Wijayawardhana S, Meegoda J, Gunaratne S, Somathilaka M, Chang K SAGE Open Med Case Rep. 2023; 11:2050313X231220826.

PMID: 38149118 PMC: 10750505. DOI: 10.1177/2050313X231220826.

Expanding the Clinical Utility of Targeted RNA Sequencing Panels beyond Gene Fusions to Complex, Intragenic Structural Rearrangements.

Schieffer K, Moccia A, Bucknor B, Stonerock E, Jayaraman V, Jenkins H Cancers (Basel). 2023; 15(17).

PMID: 37686670 PMC: 10486946. DOI: 10.3390/cancers15174394.

References

Knezevich S, Garnett M, Pysher T, Beckwith J, Grundy P, Sorensen P . ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 1998; 58(22):5046-8. View

Little S, Bax D, Rodriguez-Pinilla M, Natrajan R, Messahel B, Pritchard-Jones K . Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney. Clin Cancer Res. 2007; 13(15 Pt 1):4360-4. DOI: 10.1158/1078-0432.CCR-07-0398. View

Church A, Calicchio M, Nardi V, Skalova A, Pinto A, Dillon D . Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2017; 31(3):463-473. DOI: 10.1038/modpathol.2017.127. View

Anderson J, Gibson S, Sebire N . Expression of ETV6-NTRK in classical, cellular and mixed subtypes of congenital mesoblastic nephroma. Histopathology. 2006; 48(6):748-53. DOI: 10.1111/j.1365-2559.2006.02400.x. View

Konicek B, Capen A, Credille K, Ebert P, Falcon B, Heady G . Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors. Oncotarget. 2018; 9(17):13796-13806. PMC: 5862616. DOI: 10.18632/oncotarget.24488. View

Argani P, Fritsch M, Kadkol S, Schuster A, Beckwith J, Perlman E . Detection of the ETV6-NTRK3 chimeric RNA of infantile fibrosarcoma/cellular congenital mesoblastic nephroma in paraffin-embedded tissue: application to challenging pediatric renal stromal tumors. Mod Pathol. 2000; 13(1):29-36. DOI: 10.1038/modpathol.3880006. View

Urano M, Nagao T, Miyabe S, Ishibashi K, Higuchi K, Kuroda M . Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers. Hum Pathol. 2014; 46(1):94-103. DOI: 10.1016/j.humpath.2014.09.012. View

Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A . A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J. 2002; 21(3):303-13. PMC: 125825. DOI: 10.1093/emboj/21.3.303. View

Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S . Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 2011; 71(24):7587-96. PMC: 3242822. DOI: 10.1158/0008-5472.CAN-11-0821. View

10.

Imielinski M, Berger A, Hammerman P, Hernandez B, Pugh T, Hodis E . Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150(6):1107-20. PMC: 3557932. DOI: 10.1016/j.cell.2012.08.029. View

11.

Aw S, Kuick C, Yong M, Lian D, Wang S, Loh A . Novel Karyotypes and Cyclin D1 Immunoreactivity in Clear Cell Sarcoma of the Kidney. Pediatr Dev Pathol. 2015; 18(4):297-304. DOI: 10.2350/14-12-1581-OA.1. View

12.

Runkle K, Kharbanda A, Stypulkowski E, Cao X, Wang W, Garcia B . Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling. Mol Cell. 2016; 62(3):385-396. PMC: 4860254. DOI: 10.1016/j.molcel.2016.04.003. View

13.

Laetsch T, Dubois S, Mascarenhas L, Turpin B, Federman N, Albert C . Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018; 19(5):705-714. PMC: 5949072. DOI: 10.1016/S1470-2045(18)30119-0. View

14.

Wegert J, Vokuhl C, Collord G, Del Castillo Velasco-Herrera M, Farndon S, Guzzo C . Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. Nat Commun. 2018; 9(1):2378. PMC: 6006309. DOI: 10.1038/s41467-018-04650-6. View

15.

Grovdal L, Stang E, Sorkin A, Madshus I . Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res. 2004; 300(2):388-95. DOI: 10.1016/j.yexcr.2004.07.003. View

16.

Vokuhl C, Nourkami-Tutdibi N, Furtwangler R, Gessler M, Graf N, Leuschner I . ETV6-NTRK3 in congenital mesoblastic nephroma: A report of the SIOP/GPOH nephroblastoma study. Pediatr Blood Cancer. 2017; 65(4). DOI: 10.1002/pbc.26925. View

17.

Baik C, Wu D, Smith C, Martins R, Pritchard C . Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication. J Thorac Oncol. 2015; 10(10):e97-9. DOI: 10.1097/JTO.0000000000000586. View

18.

Uddin N, Minhas K, Abdul-Ghafar J, Ahmed A, Ahmad Z . Expression of cyclin D1 in clear cell sarcoma of kidney. Is it useful in differentiating it from its histological mimics?. Diagn Pathol. 2019; 14(1):13. PMC: 6368701. DOI: 10.1186/s13000-019-0790-8. View

19.

Fenstermaker R, Ciesielski M . Deletion and tandem duplication of exons 2 - 7 in the epidermal growth factor receptor gene of a human malignant glioma. Oncogene. 2000; 19(39):4542-8. DOI: 10.1038/sj.onc.1203802. View

20.

Kao Y, Fletcher C, Alaggio R, Wexler L, Zhang L, Sung Y . Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma. Am J Surg Pathol. 2017; 42(1):28-38. PMC: 5730460. DOI: 10.1097/PAS.0000000000000938. View